Nkarta (NKTX) Current Assets (2019 - 2026)
Nkarta (NKTX) posted quarterly Current Assets of $235.9 million for Q1 2026, down 13.13% year-over-year from $271.6 million in Q1 2025, and down 16.5% quarter-over-quarter from $282.5 million in Q4 2025.
Nkarta (NKTX) Current Assets (2019 - 2026) Analysis & Trends
Nkarta's Current Assets history runs 8 years deep, the most recent figure standing at $235.9 million for Q1 2026.
- In Q1 2026, Current Assets fell 13.13% year-over-year to $235.9 million; the TTM figure through Mar 2026 stood at $235.9 million (down 13.13% YoY), while the FY2025 annual figure was $282.5 million, up 3.36% from the prior year.
- Current Assets for Q1 2026 stood at $235.9 million, down from $282.5 million in the prior quarter.
- The five-year high for Current Assets was $442.8 million in Q1 2024, with the low at $223.2 million in Q1 2022.
- The 5-year median for Current Assets is $289.3 million (2025), against an average of $310.0 million.
- The sharpest annual moves came in 2022 and 2025: Current Assets soared 51.5% in 2022, then slumped 38.67% in 2025.
- Nkarta's Current Assets stood at $360.7 million in 2022, then declined by 29.84% to $253.1 million in 2023, then grew by 8.01% to $273.3 million in 2024, then advanced by 3.36% to $282.5 million in 2025, then retreated by 16.5% to $235.9 million in 2026.
- Business Quant data shows NKTX's Current Assets at $235.9 million in Q1 2026, $282.5 million in Q4 2025, and $289.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 188.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188.05 Mn |
| Mar 31, 2026 | 235.89 Mn |
| Dec 31, 2025 | 282.51 Mn |
| Sep 30, 2025 | 289.28 Mn |
| Jun 30, 2025 | 296.57 Mn |
| Mar 31, 2025 | 271.55 Mn |
| Dec 31, 2024 | 273.34 Mn |
| Sep 30, 2024 | 290.15 Mn |
| Jun 30, 2024 | 331.80 Mn |
| Mar 31, 2024 | 442.78 Mn |
| Dec 31, 2023 | 253.07 Mn |
| Sep 30, 2023 | 281.19 Mn |
| Jun 30, 2023 | 286.74 Mn |
| Mar 31, 2023 | 332.19 Mn |
| Dec 31, 2022 | 360.69 Mn |
| Sep 30, 2022 | 400.92 Mn |
| Jun 30, 2022 | 417.38 Mn |
| Mar 31, 2022 | 223.22 Mn |
| Dec 31, 2021 | 245.78 Mn |
| Sep 30, 2021 | 264.64 Mn |